The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
 
Anne C. Chiang
Consulting or Advisory Role - Genentech; Genentech/Roche
Research Funding - Boehringer Ingelheim; Millennium; OncoMed; Onyx
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AVEO; Boehringer Ingelheim; Celgene; GlaxoSmithKline; Merck; Novartis
Research Funding - Biomarin
 
Alexander I. Spira
Honoraria - Novartis; Roche
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; MedImmune; Roche
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Roche
 
Robert M. Jotte
Honoraria - Bristol-Myers Squibb; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Lilly
 
Shirish M. Gadgeel
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - Genentech/Roche
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
 
Alain C. Mita
Speakers' Bureau - Genentech
 
Lowell L. Hart
Research Funding - OncoMed (Inst)
 
William Larry Gluck
No Relationships to Disclose
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Genentech; Perthera
 
Ann M. Kapoun
Employment - OncoMed
Leadership - OncoMed
Stock and Other Ownership Interests - OncoMed
Patents, Royalties, Other Intellectual Property - co-author of patents filed at OncoMed (Inst)
Travel, Accommodations, Expenses - OncoMed
 
Lu Xu
Employment - Oncomed
Stock and Other Ownership Interests - OncoMed
 
Dawn Hill
Employment - OncoMed
Stock and Other Ownership Interests - OncoMed
 
Lei Zhou
Stock and Other Ownership Interests - OncoMed
Consulting or Advisory Role - OncoMed
 
Jakob Dupont
Employment - Oncomed
Leadership - OncoMed
Stock and Other Ownership Interests - OncoMed
 
David R. Spigel
Stock and Other Ownership Interests - Foundation Medicine; Illumina
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
Speakers' Bureau - Novartis
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BIND Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Immunogen (Inst); Lilly (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer